Sugi Predict

Sugi Predict / Compounds / SCHEMBL6375544

SCHEMBL6375544

SCHEMBL6375544

CCNc1ccc(OCc2ccccc2)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 3/20 0.60
▸ CTSL P07711 3/20 0.60
▸ KMT2A Q03164 5/20 0.57
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ HPGD P15428 1/20 0.56
▸ MRGPRX1 Q96LB2 3/20 0.55
▸ F2 P00734 1/20 0.55
▸ F10 P00742 1/20 0.55
▸ PRSS1 P07477 1/20 0.55
▸ F7 P08709 1/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ ALOX12 P18054 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8747237 0.99 CTSV (0.58) CTSVCTSLKMT2ANPC1RAB9A
SCHEMBL6376682 0.94 C5AR1 (0.54) CTSVCTSLKMT2ANPC1RAB9A
Hydrochloric Acid SCHEMBL28464909 0.93 C5AR1 (0.53) CTSVCTSLKMT2ANPC1RAB9A
SCHEMBL10710278 0.92 C5AR1 (0.58) CTSVCTSLKMT2ANPC1RAB9A
SCHEMBL22967590 0.85 EGFR (0.52) CTSVCTSLKMT2ASMN1; SMN2L3MBTL1
SCHEMBL13996563 0.82 ACP1 (0.53) KMT2ANPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5506635 0.81 MAPT (0.54) KMT2ANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL30480119 0.81 MAPT (0.56) KMT2ASMN1; SMN2L3MBTL1ALDH1A1MAPT
SCHEMBL423387 0.81 MAPT (0.56) KMT2ASMN1; SMN2L3MBTL1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL7102293 0.79 MAPT (0.54) KMT2ASMN1; SMN2L3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2848617-B1 DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2022-01-12 — — EP disclosed
US-9751882-B2 Diaryl[A, G]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof KINGSOUND & PARTNER (CN) 2017-09-05 — — US disclosed
US-9359372-B2 Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-06-07 — — US disclosed
US-20150210711-A1 HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI INST MATERIA MEDICA (CN) 2015-07-30 — — US disclosed
US-20150141419-A1 DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2015-05-21 — — US disclosed
EP-2848617-A1 DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2015-03-18 — — EP disclosed
US-20140088130-A1 HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2014-03-27 — — US disclosed
EP-1274687-B1 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-01-05 — — EP disclosed
US-6703392-B2 OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT ACTELION PHARMACEUTICALS LTD. (CH) 2004-03-09 — — US disclosed
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2003-09-18 — — US disclosed
EP-1274687-A1 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2003-01-15 — — EP disclosed
WO-2001068609-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2001-09-20 — — WO disclosed
US-4191765-A 1-Aryloxy-2-hydroxy-3-aminopropanes HOECHST AKTIENGESELLSCHAFT (DE) 1980-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088130-A1 HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF HTR5A, HTR1A, HTR2C CTSV 1998/4885CTSL 3006/4885KMT2A 2339/4885
US-20150141419-A1 DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF HTR5A, HTR1F, QDPR CTSV 2146/4885CTSL 805/4885KMT2A 3312/4885
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives HCRTR2, HCRTR1, NPY2R CTSV 2499/4885CTSL 2845/4885KMT2A 1396/4885
US-20150210711-A1 HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF HTR5A, HTR1A, HTR2C CTSV 1998/4885CTSL 3006/4885KMT2A 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.